Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04FDN
|
|||
| Former ID |
DNCL002263
|
|||
| Drug Name |
Palifosfamide
|
|||
| Synonyms |
ZIO-201
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Phase 2 | [1] | |
| Company |
ZIOPHARM Oncology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C4H11Cl2N2O2P
|
|||
| Canonical SMILES |
C(CCl)NP(=O)(NCCCl)O
|
|||
| InChI |
1S/C4H11Cl2N2O2P/c5-1-3-7-11(9,10)8-4-2-6/h1-4H2,(H3,7,8,9,10)
|
|||
| InChIKey |
BKCJZNIZRWYHBN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 31645-39-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:80566
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA [cytosine-5]-methyltransferase 1 (DNMT1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cysteine and methionine metabolism | |||
| Metabolic pathways | ||||
| MicroRNAs in cancer | ||||
| Pathwhiz Pathway | Methionine Metabolism | |||
| Pathway Interaction Database | Regulation of retinoblastoma protein | |||
| Reactome | PRC2 methylates histones and DNA | |||
| NoRC negatively regulates rRNA expression | ||||
| DNA methylation | ||||
| WikiPathways | Trans-sulfuration and one carbon metabolism | |||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Trans-sulfuration pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01808534) Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.